ARTICLE | Company News
Laboratoire francais, TG Therapeutics deal
March 5, 2012 8:00 AM UTC
TG Therapeutics said that in January it exercised an exclusive, worldwide option to license from former parent company LFB rights to develop and commercialize ublituximab ( LFB-R603). The chimeric recombinant mAb against CD20 has completed a Phase I/II trial in patients with relapsed chronic lymphocytic leukemia (CLL). TG Therapeutics plans to develop ublituximab for B cell proliferative disorders. Details were not disclosed. ...